Financial Data and Key Metrics Changes - The combined net revenue for Q3 2025 was approximately $3.1 million, representing a 4% increase compared to Q2 2025 revenue of approximately $3 million, and equaled Q3 2024 revenue of approximately $3.1 million [4][19] - Loss from operations decreased by $24,000 from $7.2 million in Q3 2024 to $7.3 million in Q3 2025 [19] - Non-GAAP recurring EBITDA for Q3 2025 was a net loss of $8.9 million, compared to a loss of $9.2 million in Q3 2024 [20] - Net loss attributable to common shareholders decreased by $352,000 from $9.9 million in Q3 2024 to $9.5 million in Q3 2025 [20] Business Line Data and Key Metrics Changes - Mytesi prescription volume increased by approximately 0.9% in Q3 2025 over Q2 2025, but decreased by 3.6% compared to Q3 2024 [19] Company Strategy and Development Direction - The company aims to negotiate business development partnerships for licensed rights to develop and commercialize late-stage health products, focusing on generating non-dilutive funding [5][21] - Key late-stage initiatives include crofelemer for orphan indications related to intestinal failure and cancer therapy-related diarrhea, with plans for expedited regulatory pathways [12][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the convergence of key clinical and regulatory catalysts expected to enhance value for stakeholders, including patients and shareholders [5][21] - The company anticipates significant collaborations and licensing deals that will support late-stage product development and regulatory approval [21] Other Important Information - Crofelemer has shown a groundbreaking reduction of parenteral support by up to 37% for patients with intestinal failure, which is significant given the lack of approved treatments for MVID [9][10] - The company is in discussions with multiple potential partners for the commercialization of Canalivia, an animal health product for chemotherapy-induced diarrhea in dogs [16] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session.